Alcon delivered a strong fourth quarter with sales reaching $2.7 billion, a 9% increase over the prior year. While reported operating margins and EPS faced pressure from increased R&D and marketing investments for new launches, core results remained resilient with core diluted EPS growing 8%. The company successfully navigated softer markets through price increases and a wave of innovative product introductions in both Surgical and Vision Care segments.
Q4 sales grew 9% to $2.7 billion, or 7% on a constant currency basis, led by strong performance in equipment and ocular health.
Core diluted EPS increased 8% to $0.78, despite significant investments in R&D and sales and marketing for new product platforms.
The Surgical segment saw 21% growth in Equipment/other, driven by the launch of the Unity platform.
Vision Care growth was bolstered by a 14% increase in Ocular health sales, specifically from dry eye products like Tryptyr and Systane.
Alcon expects 2026 to be a year of sustainable growth with constant currency net sales growth of 5% to 7% and significant core operating margin expansion.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance